X
[{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Anokion SA"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calypso Biotech Doses First Patient First Phase 1 Cohort with Anti-IL-15 Monoclonal Antibody CALY-002 to Treat Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Calypso Biotech SA"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Positive Data from Phase 1 ACED Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Anokion SA"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$250.0 million","newsHeadline":"Calypso Enters into Agreement to be Acquired by Novartis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Calypso Biotech SA"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications. CALY-002 is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.
Lead Product(s):
CALY-002
Therapeutic Area: Gastroenterology
Product Name: CALY-002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: $425.0 million
Upfront Cash: $250.0 million
Deal Type: Acquisition
January 08, 2024
Details:
KAN-101 is an investigational drug that aims to re-educate the immune cells that drive celiac disease, so they do not respond to gluten antigens, while leaving the healthy components of the immune system intact.
Lead Product(s):
KAN-101
Therapeutic Area: Gastroenterology
Product Name: KAN-101
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Kanyos Bio
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 23, 2022
Details:
Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. The study is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb (CALY-002).
Lead Product(s):
CALY-002
Therapeutic Area: Gastroenterology
Product Name: CALY-002
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 16, 2020
Details:
First-in-human study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten-free diet (GFD).
Lead Product(s):
KAN-101
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 27, 2020